silodosin has been researched along with Premature-Ejaculation* in 6 studies
1 review(s) available for silodosin and Premature-Ejaculation
Article | Year |
---|---|
The efficacy and safety of silodosin for the treatment of ureteral stones: a systematic review and meta-analysis.
To evaluate the efficacy and safety of silodosin as a medical expulsive therapy for ureteral stones by means of a systematic review and meta-analysis.. We searched MEDLINE, EMBASE and the Cochrane Controlled Trials Register to identify randomized controlled trials (RCTs) of silodosin in the treatment of ureteral stones. The reference lists of retrieved studies were also investigated.. Six RCTs, including 916 participants and comparing silodosin with controls, were used in the meta-analysis. Silodosin was superior to controls in terms of stone expulsion rate, the primary efficacy end point in all six RCTs (odds ratio [OR] for expulsion 2.16, 95 % confidence interval [CI] 1.62 to 2.86, p <0.00001). Silodosin was also more effective for secondary efficacy end points; the stone expulsion time (standardized mean difference [SMD] -3.66, 95 % CI -6.61 to -0.71; p =0.01) and analgesic requirements (SMD -0.89, 95 % CI -1.19 to -0.60; p < 0.00001) were significantly reduced compared with those of controls. Other than the incidence of abnormal ejaculation, which was higher in the silodosin groups (OR 2.84, 95 % CI 1.56 to 5.16, p =0.0006), few adverse effects were observed.. This meta-analysis indicates silodosin is an effective and safe treatment option for ureteral stones with a low occurrence of side effects. Topics: Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Male; Premature Ejaculation; Prevalence; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome; Ureterolithiasis; Urological Agents | 2016 |
2 trial(s) available for silodosin and Premature-Ejaculation
Article | Year |
---|---|
Silodosin versus naftopidil in the treatment of premature ejaculation: A prospective multicenter trial.
To determine the efficacy of two α1-adrenoceptor antagonists with different affinities for α1-adrenoceptor subtypes, silodosin and naftopidil, in the treatment of premature ejaculation.. This was a prospective, open-label, multicenter trial. A total of 26 patients with untreated acquired premature ejaculation were enrolled. Premature ejaculation was defined based on the International Society for Sexual Medicine recommendation. Patients self-administered on demand silodosin 4 mg or naftopidil 25 mg 1 h before intercourse, alternating drugs at least three times each. Clinical global impression change for premature ejaculation, premature ejaculation profile, and intravaginal ejaculation latency time were evaluated at baseline and during treatment.. Due to clinical global impression change, 24 patients (92%) and 12 patients (46%) reported improvement in their own premature ejaculation problems under silodosin and nafitopidil administration, respectively. Silodosin treatment produced a significantly higher improvement rate compared with naftopidil (P = 0.0002). Objectively, silodosin significantly prolonged intravaginal ejaculation latency time compared with baseline and naftopidil (P < 0.01). Mean intravaginal ejaculation latency times were 1.9, 4.1, and 7.6 min at baseline, control and with silodosin, respectively. The rate of reduced semen volume during silodosin treatment was higher than during naftopidil treatment. There were no adverse systemic effects in either group.. Silodosin, a highly selective α1A-adrenoceptor antagonist, produces greater improvements in premature ejaculation profiles and related symptoms along with intravaginal ejaculation latency time in acquired premature ejaculation patients with or without erectile dysfunction. This result supports the clinical use of silodosin as an alternative treatment for premature ejaculation. Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Humans; Indoles; Male; Middle Aged; Naphthalenes; Piperazines; Premature Ejaculation; Prospective Studies; Self Administration; Time Factors; Treatment Outcome; Urological Agents; Young Adult | 2017 |
Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH.
To evaluate the long-term safety (primary objective) and efficacy/impact on quality of life (QoL, secondary objectives) of silodosin 8 mg once daily in men with LUTS/BPH.. Men who completed the 12-week double-blind study with silodosin 8 mg, tamsulosin 0.4 mg, or placebo were offered to continue with the 9-month open-label study during which all patients received silodosin 8 mg once daily. Safety was assessed by analysing vital signs, electrocardiograms, laboratory tests, and adverse events. Efficacy was evaluated with the International Prostate Symptom Score (IPSS), IPSS voiding and storage sub-scores, IPSS-QoL, and maximum urinary flow rate (Q max).. A total of 500 patients (mean age 66 years) entered the 9-month open-label study. Treatment-emergent adverse events (TEAE) were experienced by 33.4% patients. Ejaculation dysfunction was the most common TEAE (9.0%) but led to study discontinuations in only 1.6% of patients. Dizziness without orthostatic hypotension occurred in 0.8%. A marked reduction in total IPSS (-2.7 ± 3.8) was documented at the first visit of this extension phase in patients having de novo silodosin compared with lesser improvement in patients previously treated with silodosin (-0.82 ± 4.2) or tamsulosin (-0.83 ± 3.8). Improvements were maintained throughout the open-label phase. QoL also improved, with the greatest improvement in de novo silodosin patients. No relevant changes in Q max occurred.. Long-term treatment with silodosin was safe and efficacious. Abnormal ejaculation was the most common TEAE, but led to treatment discontinuation in only 1.6% of patients. Orthostatic hypotension was not seen, and only a few patients experienced dizziness. Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Incidence; Indoles; Lower Urinary Tract Symptoms; Male; Middle Aged; Premature Ejaculation; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Treatment Outcome | 2015 |
3 other study(ies) available for silodosin and Premature-Ejaculation
Article | Year |
---|---|
Editorial Comment to Silodosin versus naftopidil in the treatment of premature ejaculation: A prospective multicenter trial.
Topics: Humans; Indoles; Male; Naphthalenes; Piperazines; Premature Ejaculation; Prospective Studies | 2017 |
Re: Silodosin versus Naftopidil in the Treatment of Premature Ejaculation: A Prospective Multicenter Trial.
Topics: Humans; Indoles; Male; Naphthalenes; Piperazines; Premature Ejaculation; Prospective Studies | 2017 |
Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia.
To assess the ejaculatory disorder caused by silodosin in the prostatic hyperplasia patients who carry out sexual actions (sexual intercourse, masturbation).. The subjects of this study were 91 patients who had been clinically diagnosed to have LUTS/BPH at this hospital, who were administered silodosin at 4 mg twice a day, and who gave response to a questionnaire survey related to ejaculatory disorder. Sexual intercourse and masturbation were regarded as sexual actions in this study.. Ejaculatory disorder occurred in 38 (42%) of the 91 silodosin administration cases. Forty (44%) of the 91 patients answered that they carried out sexual actions after oral intake of silodosin. When the investigation was conducted only in those who exercised sexual actions, ejaculatory disorder was observed in 38 (95%) of these 40 patients, indicating a high incidence. When asked if disturbed by the ejaculatory disorder, 29 (76%) of the 38 patients who had ejaculatory disorder answered yes. Oral silodosin was discontinued due to the ejaculatory disorder in 2 (5%) of these patients. On the whole, the discontinuation rate of oral silodosin was 2% (2/91 patients).. It was demonstrated that the administration of silodosin induced ejaculatory disorder at a high incidence. Since it is possible that the high frequency of ejaculatory disorder by silodosin may reduce QOL, it is considered necessary to provide sufficient information related to ejaculatory disorder at the time of treatment with silodosin. Topics: Aged; Aged, 80 and over; Ejaculation; Humans; Indoles; Male; Middle Aged; Premature Ejaculation; Prostatic Hyperplasia; Surveys and Questionnaires; Treatment Outcome | 2012 |